Clinical Trial Update: Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating HL-085 in combination with Vemurafinib for metastatic colorectal cancer is ongoing, with the status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• HL-085
• Vemurafinib (vemurafenib)

Snippet

Sponsor: Shanghai Kechow Pharma, Inc. | Conditions: CRC | Phase 2 | Status: UNKNOWN